Applies to dacarbazine: powder for solution
Intravenous route (Powder for Solution)
Hemopoietic depression is the most common toxicity with dacarbazine for injection. Hepatic necrosis has also been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.
Along with its needed effects, dacarbazine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.
Check with your doctor immediately if any of the following side effects occur while taking dacarbazine:
Check with your doctor as soon as possible if any of the following side effects occur while taking dacarbazine:
Some side effects of dacarbazine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
This medicine may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.
After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:
Applies to dacarbazine: intravenous powder for injection
Very common (10% or more): Bone marrow depression (25%)
Common (1% to 10%): Anemia, leukopenia, thrombocytopenia
Rare (less than 0.1%): Pancytopenia, agranulocytosis, blood lactate dehydrogenase (LDH) increased, blood creatinine increased, blood urea increased
Very common (10% or more): Nausea (90%), vomiting (90%)
Rare (less than 0.1%): Diarrhea
Rare (less than 0.1%): Hepatic necrosis due to veno-occlusive disease (VOD) of the liver, Budd-Chiari syndrome (sometimes fatal), hepatic enzymes increased (e.g., alkaline phosphatase, ASAT, ALAT)
Rare (less than 0.1%): Facial flushing
Frequency not reported: ECG abnormalities, orthostatic hypotension (may be associated with high doses)
Rare (0.01% to 0.1%): Anaphylaxis
Uncommon (0.1% to 1%): Alopecia, hyperpigmentation, photosensitivity
Rare (less than 0.1%): Erythema, maculopapular exanthema, urticaria
Frequency not reported: Rash
Rare (less than 0.1%): Application site irritation
Frequency not reported: Severe pain along the vein caused by injection of concentrated solution, extravasation (causing pain, tissue damage, cellulitis), burning sensation
Anorexia, nausea, and vomiting are the most frequently reported adverse reactions. Over 90% of patients are affected with the initial few doses. The vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. Restricting oral intake of food for 4 to 6 hours prior to therapy may help to alleviate these symptoms. The rapid toleration of these symptoms suggests that a CNS mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days.
Uncommon (0.1% to 1%): Infections, influenza-like symptoms
Frequency not reported: Myalgia
Common (1% to 10%): Blurred vision
Rare (less than 0.1%): Impaired vision
Very common (10% or more): Anorexia (90%)
Rare (less than 0.1%): Headache, lethargy, malaise, convulsions, facial paresthesia
Rare (0.01% to 0.1%): Confusion
Rare (less than 0.1%): Impaired renal function
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Dacarbazine (www.drugs.com/mtm/dacarbazine.html).
March 27, 2020
March 27, 2020
March 28, 2020
March 27, 2020
March 24, 2020
March 26, 2020